Ligand pharmaceuticals inc LGND.US Overview Analysis
LGND AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
LGND Current Performance
0.47%
Ligand pharmaceuticals inc
2.24%
Avg of Sector
0.40%
S&P500
Top 10 High Relevance to LGND
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
TXG | 10x genomics inc | 1 | 2 | 1 | 2 | 1 | |
VCYT | Veracyte inc | 4 | 5 | 3 | 3 | 1 | |
AVXL | Anavex life sciences corp. | 1 | 5 | 4 | 1 | 1 | |
ADPT | Adaptive biotechnologies corp | 4 | 4 | 3 | 2 | 1 | |
PACB | Pacific biosciences of california inc | 2 | 3 | 2 | 1 | 1 |
- TXG 10x genomics incValue 1Trend 2Swing Trading 1Whale Interest 2Dividend 1See more
LGND Profile
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.